The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Open accessAbstract
BACKGROUND Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis. METHODS PROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin-angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850. FINDINGS Between Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-110) was -2·7 mL/min per 1·73 m2 per year versus -3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1-week 110) was -2·9 mL/min per 1·73 m2 per year versus -3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI -0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (-42·8%, 95% CI -49·8 to -35·0, with sparsentan versus -4·4%, -15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals. INTERPRETATION Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function. FUNDING Travere Therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationKDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationMultiple Imputation for Nonresponse in Surveys.
Lynn, P., & Rubin, D. B. (1988) · The Statistician · doi:10.2307/2348774 · Cited by 2,329
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
The Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
Self-citationRovin, B. H., Teng, Y. K. O., Ginzler, E. M., Arriens, C., Caster, D. J., Romero-Diaz, J., Gibson, K., Kaplan, J., Lisk, L., Navarra, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00578-x · Cited by 635
Self-citationLong-Term Outcomes in IgA Nephropathy
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000135 · Cited by 458
Self-citationWheeler, D. C., Toto, R. D., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Pecoits-Filho, R., Correa-Rotter, R., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.03.033 · Cited by 420
Self-citationLv, J., Wong, M. G., Hladunewich, M. A., Jha, V., Hooi, L. S., Monaghan, H., Zhao, M., Barbour, S., Jardine, M. J., Reich, H. N., et al. (2022) · JAMA · doi:10.1001/jama.2022.5368 · Cited by 354
Self-citation
Cited by
The pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citationAtrasentan in Patients with IgA Nephropathy
Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409415 · Cited by 142
Self-citationIptacopan in IgA Nephropathy — Final 24-Month Data
Barratt, J., Eren, N., Kashihara, N., Maes, B., Rizk, D. V., Rovin, B., Trimarchi, H., Zhang, H., Wang, W., Kocyigit, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2600743 · Cited by 34
Self-citationIgA nephropathy: Update on pathogenesis and treatment
Ramsawak, S., Cohen, S., Linares, A., & Cavanaugh, C. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24105 · Cited by 23
Metadata
- Authors
- Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., Peh, C. A., Praga, M., Preciado, P., Radhakrishnan, J., Rheault, M. N., Rote, W. E., Tang, S. C. W., Tesar, V., Trachtman, H., Trimarchi, H., Tumlin, J. A., Wong, M. G., Perkovic, V., Abbasciano, I., Abrantes, C., Accarino, S., Adler, S., Adoberg, A., Afsari, R., Ahmad, S., Ahmed, J., Ahn, W., Ajayi, B., Aksamit, D., Al Chalabi, S., Alamartine, E., Alchi, B., Ali, M., Aliotta, R., Almaani, S., Almeida, C., Almeida, E., Alvarez, F. D. L. P., Alves, P., Annese, F., Appel, G., Arduan, A. O., Arena, M., Arevalo, M. C., Arfaania, D., Arias, C., Aristoy, E. C., Asakiene, E., Ashley, S., Assefi, A., Atenza, A., Auerbach, A., Augustyniak-Bartosik, H., Avella, M., Ayling-Smith, J., Ayoub, I., Ayvazyan, C., Baccaro, R., Bailey, A., Baker, B., Balamuthusamy, S., Ballarin, J., Barata, R., Barbic, J., Barisic, D., Barratt, J., Barreto, J. C. D. J., Barrios, C., Belingheri, M., Benesova, A., Bernabeu, A. A., Bernhardt, W., Bhadra, S., Biancone, L., Blanchard, A., Boaglio, E., Bolignano, D., Bomback, A., Bonilla, G. A. U., Bordoli, M., Bose, B., Boudville, N., Brandon, D., Brandon, D., Brown, K., Broyet, C., Bucknall, T., Buffet, A., Bumblyte', I. A., Burdese, M., Burgos, N. A., Burgos, N. A., Burguet, L., Burtey, S., Busch, M., Cakiroglu, F., Campbell, V., Canetta, P., Capaccio, F., Carbonell, J., Cardoso, F., Carro, C. G., Carroll, R., Carron, P.-L., Carullo, N., Cassia, M., Caster, D., Castillo, B. V., Catucci, D., Cavalli, A., Chae, D.-W., Chakera, A., Chan, D., Chan, G. C. W., Chan, A. T. P., Chan, L. W., Chang, J. H., Chang, M.-S., Chapman, F., Charytan, C., Chaudhry, A., Cheetham, M., Chen, C.-H., Chen, H.-Y., Chen, C.-L., Chen, H.-Y., Chen, H.-C., Chenine, L., Cheung, S. F., Cheung, C. K., Chiche-Jourde, N., Chiu, H.-F., Chiu, Y.-L., Chiu, Y.-W., Chiu, I., Choi, H. Y., Chou, K.-J., Chowdhury, P., Chowdhury, P., Chrysochou, C., Chukwu, C., Chun, K. Y., Chung, W., Cieniawski, D., Claisse, G., Clayton, P., Cleary, C. M., Clement, N., Coates, T., Cogno, C., Colla, L., Collins, M., Colucci, M., Combe, C., Comi, N., Comunale, R., Contreras, G., Cooper, B., Coppock, G., Costa, A. C., Costanzi, S., Cozzolino, M., Crail, S., Cunha, L., Curry, E., Dai, T., Daina, E., Daneshvari, S., Dasgupta, I., DaSilva, L., Davidson, R., De Bhailis, A. M., de Précigout, V., Decupere, M., Delmas, Y., Deodato, F., Dhaun, N., Dhaygude, A., Dhelaria, R., Di Maio, F., Diezhandino, M. A. G., Dika, Z., Dinic, M., Dittmer, I., Dobre, M., Doctor, G., Donati, G., Doubel, P., Douthit, N., Draganova, D., Drexler, Y., Drinkovic, M., Drinovska, K., Dudreuilh, C., Dumond, C., Durlen, I., Dussol, B., Encarnacion, M. D., Endre, Z., Enrique, J., Eqbal, Y., Erlich, J., Esposito, V., Esposito, C., Fakih, F., Fang, H.-C., Farinha, A., Fearday, A., Felgueiras, J. D. S. S., Felicjanczuk, E., Fernandes, J. C., Fernandes, S., Fernandes, A., Fernandez, J. L., Fernandez, V., Fernando, M., Figueiredo, A. C., Firre, E., Floege, J., Flossmann, O., Floyd, L., Fonseca, N., Fonseca, J. N. D. A. A., Foote, C., Forbes, S., Forcen, A., Fornoni, A., Fouassier, D., Fraser, I., Fung, K. S. S., Furlano, M., Furtado, T., Gadh, R., Gaisset, R., Gallagher, M., Gameiro, J., Gangadharan, M., Garcia, F. A., Garcia, O. G., Garg, G., Garrouste, C., Gautam, A., Geara, A., Geddes, C., Gellineo, L., Germain, M., Gesualdo, L., Ghalli, F., Giaroni, F., Giles, H., Gillies, A., Gimeno, A. V., Girardet, A., Glaze, J., Goh, T., Gois, M., Goldsmith, C., Goma, E., Gomes, A. M., Goncalves, L. P. F., Goncalves, S., Gontarek-Kacprzak, J., Gonzalez, C., Gopu, A., Gowda, N., Gray, N., Greco, B., Green, H., Greze, C., Griffin, S., Guldris, S. C., Guzman, U. V., Ha, J. T. K., Hall, A., Hamilton, P., Han, S. H., Haws, R., Hayat, A., Heath, L., Heinrichs, S., Henderson, A., Henderson, A., Hendren, E., Heng, A.-E., Heres, S. V. P., Herfurth, J. K., Herrero, E. M., Ho, T.-Y., Hogan, J., Hohenstein, B., Hollett, P., Horvatic, I., Hsu, B.-G., Hsu, C.-T., Hsu, C.-Y., Hsu, S.-P., Huang, C.-W., Hudson, A., Hung, C.-C., Hwang, S.-J., Hwang, D.-Y., Hyun, Y. Y., Ilmoja, M., Irish, G., Jacob, R., Jahan, S., Jain, A., Jamar, S., Jander, A., Jang, H. R., Janko, C., Jardine, M., Jaskowski, P., Jeantet, G., Jelakovic, B., Jeon, J., Jeong, J. C., Jesudason, S., Jittirat, A., Jo, S.-K., Jones, R., Joo, N., Jorge, S., Julian, B., Jung, J., Jyothinagaram, P., Kadakia, J., Kamal, F., Kanigicherla, D., Karanovic, S., Karras, A., Kasimatis, T., Kassem, M., Kattamanchi, S., Keller, C., Kentric, D. T., Kettner, C., Khalil, K., Kim, D., Kim, S. J., Kim, Y. H., Kim, Y., Kim, H. W., Kim, S., Kim, J.-K., Kim, A., Kim, M.-G., Kimber, C., Klamm, K., Koch, A., Koester, E., Kolvald, K., Kon, S., Kooienga, L. A., Kotwal, S., Krajewska, M., Kratka, K., Krishnan, A., Krishnasamy, R., Krueger, T., Kruljac, I., Kulka, S., Kunzendorf, U., Kuo, M.-C., Kuo, H.-T., Kuo, S., Kwan, L. P. Y., Kwella, N., Kwella, B., Kyaw, K., Labat, A., Lafayette, R., Lagatta, M., Lam, C. K. D., Lambie, M., Lanaret, C., Latif, F., Laute, M., Law, W. P., Lawman, S., Lazo, M. S., Lee, H., Lee, M. H., Lee, K.-B., Lee, H.-S., Lee, J., Lee, H. H., Lee, P.-T., Leis, L., Lemahieu, W., Leung, J., Li, Y., Lie, D. N. W., Lifland, H., Lilienthal, K., Lim, W., Limardo, M., Livrozet, M., Longhi, S., Lopes, D., Lopes, J. A., Lorde, N., Luxton, G., Ma, M., Madhrira, M., Madonia, P., Maes, B., Mahadevan, K., Mahdi, A., Mahdi, E., Maillard, N., Maixnerova, D., Majstorovic Barac, K., Malecki, R., Malfait, T., Malvica, S., Mandayam, S., Manley, P., Mansfield, N., Marcantoni, C., Mariat, C., Marin, T. M., Marin, L. M. R., Mark, P., Marques, J., Martinez, E. G., Martinez, S., Masset, C., Masson, I., Mather, A., Maung Myint, T. M., Mayet, V., McCafferty, K., McCarthy, E., McDonald, S., McGreal, K., McMahon, K., McNally, A., McQuarrie, E., Medina, A., Meeus, G., Mehta, K., Mendoza, E., Menezes, M., Meng, J., Messa, P., Messias, A., Miarka, P., Miglinas, M., Mikacic, I., Mikhail, A., Milicevic, M., Minasian, R., Moeller, M., Mohey, H., Mojarrab, J., Mok, M. M. Y., Moncasi, E. P., Moonen, M., Morales, W. A. A., Moreno, E. V., Moreno, A., Morris, A., Moutzouris, D., Moya, M. G., Mucha, S., Musolino, M., Napodano, P., Natario, A., Negrea, L., Nelson, B., Neuen, B., Newsome, B., Ng, K. C. J., Nguyen, T., Nguyen, V., Nicolo, C., Nitschke, M., Noble, E., Noble, E., Nolasco, F., O'Lone, E., Ochoa, A. S., Oh, K.-H., Oh, S., Okoh, P., Ombelet, S., O'Shaughnessy, M., Ou, S.-H., Packham, D., Padiyar, A., Pai, M.-F., Pamplona, I. A., Pan, S.-Y., Pandya, B., Papadia, F., Pardinhas, C., Parikh, N., Parikh, S., Park, H. C., Park, J. T., Parreira, L., Passerini, P., Patak, R., Patecki, M., Patel, R., Patel, J., Patel Suthar, M., Patella, G., Patrikyan, A., Pavlovic, D., Paxton, W., Peh, C., Peleg, Y., Pelicano, J. M. B., Peng, Y.-S., Pereira de Vicente, M., Perez, J. P., Perez, E., Perez de Jose, A., Pérez Gómez, M. V., Perez Lluna, L., Peri, U., Perico, N., Philipponnet, C., Phua, E., Piel, J., Pillai, U., Pilmore, H., Plavljanic, D., Plaza, M. V., Pollock, C., Ponnusamy, A., Ponti, S., Powell, T., Pradhan, N., Prado, R. F., Prkacin, I., Pruthi, R., Pugh, D., Quinn, S., Quintana, L. F., Raakesh, L., Rabindranath, K., Radermacher, L., Radhakrishnan, J., Ragy, O. S. I., Raichoudhury, R., Raimundo, M., Randone, P., Razavian, M., Reichel, H., Reis, M., Remuzzi, G., Reynolds, A., Ricchiuto, A., Rico, I. M. B., Rigothier, C., Ritchie, A., Rivero, M. A. A., Rizk, D., Ro, H., Rodriguez, A., Rodriguez Garcia, E., Roger, S., Rony, M., Rosenberg, M., Roueff, S., Rovin, B., Roxburgh, S., Ruiz, M., Rusinol, H. M., Rychlik, I., Sá, H., Salehi, T., Sánchez de la Nieta, M. D., Sanden, S., Santockiene, L., Santos, P. V., Santos, I. D. S., Sargsyan, M., Sarnow, F., Sat, S., Satora, E., Savuk, A., Sayer, M., Schlieper, G., Schlosser, M., Schmidt-Guertler, H., Schockaert, O., Schulte, K., Schulz, L., Selvaskandan, H., Semple, D., Sen, S., Seppet, E., Serrano, A. G., Serre, J.-E., Sevillano, A., Shah, S., Shen, Y., Sheridan, B., Shu, K.-H., Sightler, F., Silva, S., Silva, A., Sinha, S., Siriwardana, A., Sitas, Z., Sivo, C., Sizeland, P., Sly, C., Smith, P., Snow, B., Soares, E. S. Q., Solazzo, A., Solis, E. G., Solomon, L., Song, Y. R., Sousa, H., Spinowitz, B., Stallworthy, E., Stamellou, E., Stanczyk, M., Stangenberg, S., Stankovic, M., Stankuviene, A., Stea, E. D., Stompor, T., Storrar, J., Sullivan, J., Sulowicz, W., Suyumova, I., Szeto, C. C., Tamarit, E., Tan, E., Tan, M., Tang, S. C. W., Tang, H., Teixeira, C., Telling, K., Terrades, N. R., Tesar, V., Tez, D., Thervet, E., Thibaudin, D., Thomas, M., Thyagarajan, N., Tkaczyk, M., Torreggiani, M., Trillini, M., Tsai, S.-F., Tsai, W.-C., Tsai, J.-C., Tseng, P.-Y., Tumlin, J., Tung, K.-T., Turnbull, A., Udani, S., Uhlinova, J., Unt, K., Urciuolo, F., Vanacker, A., Vandewiele, B., Vaz, A., Veermae, K., Viaene, L., Vickiene, A., Vigano, S., Vila, M. A. M., Vilayur, E., Villanueva, C. M., Villarroya, C. M., Villen, A. S., Viramontes, V., Vita, C., Vujcic, D., Wahba, M., Wan, S., Wang, C.-H., Warling, X., Waters, G., Waugh, J., Weiland, L., Weiner, S., Weinreich, T., Werth, S. C., Wickens, O., Wijeratne, V., Wilder, K., Willcocks, L., Williams, A., Winiarska, A., Wirtz, N., Wolf, L., Wolf, G., Wong, M. G., Wong, Y. H., Wong, S. H. S., Workeneh, B., Wu, M.-J., Wu, H.-Y., Wyndham, R., Yang, J., Yang, J.-Y., Yeap, C., Yim, K. F., Yong, K., Yoo, T.-H., Yoon, S., Yu, T.-M., Yue, T. T. A., Zakari, M., Zakauskiene, U., Zaoui, P., Zbrzezniak, J., Zielinska, D., & Zizzi, C. F.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-12
- Volume
- 402
- Issue
- 10417
- Pages
- 2077-2090
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4388304602
- Cited by
- 307
- References
- 26
- FWCI
- 50.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)02302-4
- The paper
- Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., Kohan, D. E., Komers, R., Kooienga, L. A., Lafayette, R., Maes, B., Małecki, R., Mercer, A., Noronha, I. L., Oh, S. W., . . . Zizzi, C. F. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)02302-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.